What Did the First U.S. Phase 2 Mazdutide Trial Show for Weight Loss, HbA1c, and Tolerability in 2026?

The first United States phase 2 trial of mazdutide reported dose-dependent weight reductions of up to 18% at 32 weeks in adults with obesity or overweight. Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist. All active doses produced significant HbA1c decreases versus placebo. Gastrointestinal adverse events were the dominant tolerability signal with discontinuation rates reaching 20% at 16 mg.

What Was the Design of the U.S. Phase 2 Mazdutide Trial?

Hsia and colleagues conducted a multicentre randomised placebo-controlled phase 2 trial published in The Lancet Diabetes and Endocrinology in August 2026. Adults with obesity or overweight without type 2 diabetes were allocated to placebo or mazdutide 3–6 mg, 10 mg, or 16 mg once weekly by subcutaneous injection. The primary endpoint was percentage change in body weight at week 32.

Mazdutide (IBI362) is co-developed by Innovent Biologics and Eli Lilly and Company. It is a synthetic peptide engineered to activate both the glucagon-like peptide-1 receptor and the glucagon receptor with balanced potency. The United States trial was the first phase 2 efficacy and safety readout in a Western population, extending earlier Chinese data to a geographically distinct cohort.

Dose escalation followed a structured titration schedule designed to manage gastrointestinal tolerability. The 3–6 mg arm began at 3 mg and escalated to 6 mg. The 10 mg arm escalated stepwise to 10 mg and the 16 mg arm escalated to 16 mg. The trial ran to at least 48 weeks with week 32 as the pre-specified primary analysis window.

What Weight-Loss Outcomes Did the U.S. Phase 2 Trial Report?

At week 32 the 3–6 mg arm achieved approximately 7% mean body-weight reduction. The 10 mg arm achieved approximately 15% and the 16 mg arm achieved approximately 18%, versus minimal change with placebo. All active arms achieved statistically significant reductions. Weight-loss curves had not plateaued by week 32.

By week 48 weight loss deepened further. The 3–6 mg group reached approximately 11%, the 10 mg group approximately 19%, and the 16 mg group approximately 22%. The absence of a plateau is mechanistically consistent with dual GLP-1R/GCGR agonism where sustained glucagon receptor activation maintains elevated energy expenditure.

Hsia noted at ObesityWeek 2024 in Atlanta that "all of these mazdutide treatment curves did not seem to plateau," supporting the hypothesis that longer treatment durations may yield additional weight reduction. These deepening curves distinguish mazdutide's 48-week trajectory from that of semaglutide where weight loss typically plateaus by 36–40 weeks.

These figures compare favourably with the 11–15% weight loss range reported for mazdutide in earlier Chinese phase 2 trials at doses up to 9 mg over 24–48 weeks. The higher ceiling in the United States trial reflects the inclusion of the 16 mg dose arm not previously studied at phase 2 scale. A separate high-dose phase 1 study in Western participants confirmed that 16 mg was associated with 20–21% weight loss.

What Were the HbA1c and Glycaemic Outcomes?

All mazdutide dose arms produced statistically significant decreases in HbA1c versus placebo despite the trial enrolling participants without type 2 diabetes. The glycaemic signal reflects GCGR-mediated suppression of hepatic glucose output combined with GLP-1R-driven enhancement of glucose-dependent insulin secretion. HbA1c reductions were consistent across doses without a clear dose-response gradient between arms.

The absence of a steep dose-response gradient for HbA1c contrasts with the clear dose-response seen for body weight. In earlier Chinese phase 2 data, mazdutide titrated to 10 mg achieved HbA1c reduction of approximately 2% versus placebo in participants with type 2 diabetes. In the United States trial's non-diabetic population, lower baseline HbA1c values compressed the absolute reduction range.

The signal nonetheless confirms that mazdutide's glucoregulatory activity is present across metabolic phenotypes including those without established diabetes. This is clinically relevant for the prediabetes and metabolic syndrome populations most likely to be enrolled in future United States phase 3 trials.

In the separate DREAMS-3 phase 3 trial in Chinese adults with type 2 diabetes and obesity, mazdutide 6 mg achieved a mean HbA1c reduction of approximately 2% from baseline at week 32. Additionally, 48% of participants met the dual endpoint of HbA1c below 7% and at least 10% body-weight reduction. These phase 3 data provide a higher-powered glycaemic benchmark though direct cross-trial comparison is limited by population differences.

What Lipid and Cardiometabolic Effects Were Observed?

Participants in the 10 mg and 16 mg dose arms experienced statistically significant declines in LDL cholesterol and non-HDL cholesterol, effects not observed at the 3–6 mg dose. The lipid-lowering signal is attributed to GCGR-mediated upregulation of hepatic LDL receptor expression and enhanced hepatic fatty acid oxidation, both downstream consequences of glucagon receptor activation in the liver.

Glucagon receptor agonism promotes hepatic lipid clearance through multiple mechanisms. It increases mitochondrial beta-oxidation, suppresses de novo lipogenesis, and upregulates LDL receptor transcription via a pathway partially independent of PCSK9 regulation. These hepatic effects are dose-dependent and emerge most clearly at higher mazdutide doses where GCGR occupancy is sufficient to drive meaningful transcriptional changes.

Blood pressure and heart rate data were collected as secondary endpoints. Modest reductions in systolic blood pressure were observed across active arms consistent with the weight-loss magnitude. Heart rate changes were not reported as a primary safety signal in the United States phase 2 data. This distinguishes mazdutide's profile from retatrutide where resting heart rate elevation is a documented dose-dependent finding.

What Was the Tolerability and Adverse-Event Profile?

Gastrointestinal adverse events were the most common treatment-emergent events and were predominantly mild to moderate in severity. The principal events were nausea, vomiting, and diarrhoea. Discontinuation due to adverse events increased with dose reaching approximately 20% in the 16 mg arm. No new safety signals beyond the GI class were identified across any dose group.

The GI adverse-event profile is mechanistically expected for GLP-1R agonists and is not unique to the dual-agonist class. GLP-1R activation slows gastric emptying and reduces gastrointestinal motility producing nausea and vomiting concentrated in the dose-escalation phase. These effects generally attenuate with continued treatment once the target dose is reached and maintained.

The structured titration protocol in the United States phase 2 trial was designed to mitigate peak GI burden though the 16 mg dose arm still produced a clinically meaningful discontinuation rate. The approximately 20% discontinuation rate at 16 mg represents a dose–tolerability tradeoff that will require careful evaluation in phase 3 design.

For context, discontinuation rates due to adverse events in semaglutide 2.4 mg trials ranged from approximately 7–9% and tirzepatide phase 3 trials reported approximately 6–8%. The higher rate at mazdutide 16 mg likely reflects the steeper escalation required to reach that target dose rather than an intrinsic tolerability deficit of the molecule.

How Does Dual GLP-1R/GCGR Agonism Explain the Efficacy Profile?

Mazdutide's efficacy derives from simultaneous activation of two complementary receptor axes. GLP-1R engagement suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. GCGR activation elevates resting energy expenditure and drives hepatic lipolysis. The net effect is a larger weight-loss ceiling than GLP-1R monotherapy alone achieved through non-overlapping mechanisms.

The GCGR component is the pharmacological differentiator. Glucagon receptor agonism in adipose tissue and liver increases fatty acid oxidation and thermogenesis via a cAMP-PKA pathway raising basal metabolic rate independent of caloric restriction. This energy expenditure effect is additive to the appetite suppression mediated by GLP-1R explaining why dual agonists consistently achieve greater weight loss than GLP-1R monotherapy at equivalent tolerability thresholds.

A critical design feature of mazdutide is the ratio of GLP-1R to GCGR potency. Excessive GCGR agonism relative to GLP-1R activity risks hyperglycaemia because glucagon's primary physiological role is to raise blood glucose. Mazdutide's balanced receptor potency allows glycaemic neutrality or improvement even as glucagon receptor engagement drives metabolic benefits.

What Is Mazdutide's Current Regulatory and Approval Status?

As of 2026 mazdutide has not received FDA approval for any indication. Regulatory review is advancing in China where Innovent Biologics has submitted for approval based on phase 3 data. In the United States the Hsia phase 2 trial published in August 2026 is the most advanced human dataset available.

In China mazdutide has completed multiple phase 3 trials. These include GLORY-1 and GLORY-2 for obesity and DREAMS-3 for type 2 diabetes versus semaglutide. The GLORY-2 data showed 84% of participants achieving at least 5% body-weight loss at 60 weeks. Vomiting, nausea, and diarrhoea were the most common adverse events in those trials.

These phase 3 datasets form the basis of the Chinese regulatory submission and provide a higher-powered safety database than the United States phase 2 trial alone. Clinicians and researchers should note that mazdutide remains investigational under FDA jurisdiction. No compounding pathway exists and off-label use is not supported by an approved indication.

The United States phase 2 data establish proof-of-concept for efficacy and tolerability in a Western population but do not constitute the controlled evidence base required for regulatory approval. Any clinical use outside a registered trial would be unsupported by the current regulatory framework.

How Do the U.S. Phase 2 Data Position Mazdutide Relative to Approved Incretin Agents?

At 16 mg, mazdutide's approximately 18% mean weight loss at 32 weeks numerically exceeds semaglutide at approximately 15% at 68 weeks in STEP-1. It also approaches tirzepatide at approximately 21% at 72 weeks in SURMOUNT-1. Cross-trial comparison is confounded by differences in duration, population, and endpoint definitions. No head-to-head United States trial versus either approved agent has been conducted.

The lipid-lowering signal at higher doses adds a cardiometabolic dimension not consistently present with GLP-1R monotherapy. Semaglutide and tirzepatide do not produce consistent LDL reductions in their pivotal trials. The LDL effect observed with mazdutide 10 and 16 mg is attributable to GCGR-mediated hepatic LDL receptor upregulation representing a potentially differentiated benefit for patients with combined obesity and dyslipidaemia.

The tolerability comparison is less favourable at the highest dose. A 20% discontinuation rate at 16 mg is substantially higher than the 6–9% rates observed in semaglutide and tirzepatide phase 3 programmes. Whether this reflects the dose level tested, the titration schedule, or an intrinsic property of GCGR co-agonism will require phase 3 data to resolve.

The 10 mg arm achieved approximately 15% weight loss at 32 weeks with a lower discontinuation rate than the 16 mg arm. This may represent the more clinically viable dose for a United States phase 3 programme. This dose-selection question is among the most consequential design decisions facing the mazdutide development programme. Future phase 3 design will need to balance the efficacy ceiling of 16 mg against its tolerability burden. Does Retatrutide's Phase 3 Evidence in 2026 Show Clinically Meaningful Weight Loss Beyond Semaglutide and Tirzepatide? What Do the 2026 TRIUMPH-1 Topline Data Show for Retatrutide's Weight Loss and Cardiometabolic Endpoints at 80 Weeks? What Do the 2026 Phase 3 TRIUMPH Data Show for Retatrutide's Weight-Loss Efficacy, Cardiometabolic Effects, and Dose-Limiting Adverse Events?